Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRNASDAQ:BBNXNASDAQ:DCTHNASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$3.79-6.7%$4.35$2.34▼$8.79$146.41MN/A282,179 shs240,616 shsBBNXBeta Bionics$14.56-3.4%$15.18$8.89▼$24.50$653.38MN/A515,639 shs760,105 shsDCTHDelcath Systems$13.60+0.2%$14.69$7.17▼$18.23$472.59M0.94415,410 shs761,637 shsNPCENeuroPace$11.14+4.0%$12.85$5.45▼$18.98$351.27M2.03178,891 shs618,085 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global-6.65%-0.26%-13.07%+11.47%+378,999,900.00%BBNXBeta Bionics-3.38%-7.85%-15.35%+29.54%+1,455,999,900.00%DCTHDelcath Systems+0.22%+2.56%-15.37%+8.19%+62.49%NPCENeuroPace+4.01%+5.39%-14.18%-15.03%+47.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems3.2844 of 5 stars3.55.00.00.01.52.50.6NPCENeuroPace3.374 of 5 stars3.43.00.00.02.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 3.00Buy$16.50335.36% UpsideBBNXBeta Bionics 2.75Moderate Buy$23.4461.02% UpsideDCTHDelcath Systems 3.00Buy$24.0076.47% UpsideNPCENeuroPace 2.83Moderate Buy$15.5039.14% UpsideCurrent Analyst Ratings BreakdownLatest AVR, BBNX, NPCE, and DCTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.70M50.62N/AN/A$1.74 per share2.18BBNXBeta Bionics$65.12M9.69N/AN/A($5.72) per share-2.55DCTHDelcath Systems$37.21M12.73N/AN/A$2.15 per share6.33NPCENeuroPace$79.91M4.57N/AN/A$0.27 per share41.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/AN/ABBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/ADCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)Latest AVR, BBNX, NPCE, and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A3.673.65BBNXBeta BionicsN/A15.8814.93DCTHDelcath SystemsN/A15.9514.61NPCENeuroPace2.466.635.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ABBNXBeta BionicsN/ADCTHDelcath Systems61.12%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies GlobalN/ABBNXBeta BionicsN/ADCTHDelcath Systems17.94%NPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 millionN/AN/ABBNXBeta Bionics29443.36 millionN/AN/ADCTHDelcath Systems6034.83 million28.58 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionableAVR, BBNX, NPCE, and DCTH HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 27, 2025 | prnewswire.comNeuroPace Announces Strategic CFO Transition - MorningstarJune 26, 2025 | morningstar.comMNeuroPace, Inc.: NeuroPace Announces Strategic CFO TransitionJune 25, 2025 | finanznachrichten.deAnalysts Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $15.50June 25, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - MorningstarJune 24, 2025 | morningstar.comMNeuroPace Announces Strategic CFO TransitionJune 24, 2025 | globenewswire.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 24, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 23, 2025 | globenewswire.comPalumbo Wealth Management LLC Has $567,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE)June 23, 2025 | marketbeat.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | gurufocus.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...June 22, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 22, 2025 | prnewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comNeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician SurveyJune 17, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 16, 2025 | accessnewswire.comANeuroPace’s SWOT analysis: med tech stock poised for growth amid challengesJune 14, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 13, 2025 | accessnewswire.comABronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to ConnectJune 13, 2025 | accessnewswire.comAPotential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)June 12, 2025 | accessnewswire.comABronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach OutJune 12, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVR, BBNX, NPCE, and DCTH Company DescriptionsAnteris Technologies Global NASDAQ:AVR$3.79 -0.27 (-6.65%) As of 06/30/2025 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Beta Bionics NASDAQ:BBNX$14.56 -0.51 (-3.38%) As of 06/30/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Delcath Systems NASDAQ:DCTH$13.60 +0.03 (+0.22%) As of 06/30/2025 04:00 PM EasternDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.NeuroPace NASDAQ:NPCE$11.14 +0.43 (+4.01%) As of 06/30/2025 04:00 PM EasternNeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
